The Vita Coco Company, Inc. Form 4 Filings

Vita Coco Company, Inc. Chief Marketing Officer Jane Prior reported equity award activity on common stock. She acquired 5,914 shares through the vesting and settlement of Performance Stock Units granted in 2023 and received an additional 4,401 shares as a grant or award.

To cover tax withholding on the PSU vesting, 3,267 shares were automatically withheld in a non‑discretionary disposition mandated by the company. Following these transactions, she directly holds 129,562 shares of common stock.

Vita Coco Company, Inc. Chief Operating Officer Jonathan Burth reported equity compensation activity tied to performance and time-based awards. On February 20, 2026, 5,914 Performance Stock Units vested, converting into 5,914 shares of common stock based on 100% performance achievement.

On the same date, the company granted Burth 22,750 Performance Options and 4,401 shares of common stock as restricted stock units that vest in four equal annual installments if he remains in continuous service. In connection with the PSU vesting, 3,271 shares of common stock were automatically withheld to satisfy tax obligations in a non-discretionary transaction mandated by the company.

Following these transactions, Burth directly owned 80,891 shares of common stock and held several Non-Qualified Stock Options (rights to buy common stock), some of which are fully vested and others that vest in scheduled annual installments beginning on various dates.

Vita Coco Company, Inc. Chief Commercial Officer Charles van Es reported several equity-related transactions on February 20, 2026. A block of 5,914 Performance Stock Units vested and was converted into 5,914 shares of common stock based on 100% performance achievement.

He also received a grant of 4,401 restricted stock units that will vest in four equal annual installments, with shares automatically withheld on each vesting date to cover tax obligations. To satisfy tax withholding on the PSU vesting, 3,271 shares of common stock were withheld in a non-discretionary, issuer-mandated transaction.

After these transactions, van Es directly owned 84,672 shares of common stock. The filing also lists several non-qualified stock option awards that are fully vested or scheduled to vest over future years, reflecting ongoing equity-based compensation.

Vita Coco Company, Inc. Chief Operating Officer Jonathan Burth reported multiple equity award transactions. On February 20, 2026, he acquired 22,750 Performance Options and 4,401 shares of Common Stock as grants reported at $0.00 per share.

On the same date, 5,914 Performance Stock Units vested into Common Stock based on 100% performance achievement, and 3,271 shares were disposed of to cover tax withholding obligations in a non-discretionary transaction mandated by the company. After these transactions, his directly held Common Stock balance was 80,891 shares, alongside several Non-Qualified Stock Option holdings with various vesting schedules.

Vita Coco Company, Inc. Chief Marketing Officer Jane Prior reported several equity award transactions. She acquired 5,914 Performance Stock Units through vesting of a prior grant, based on 100% performance achievement, with each unit representing one share of common stock.

On the same date, she received 4,401 restricted stock units that vest in four equal annual installments, generally with shares withheld at vesting to cover taxes in non-discretionary transactions. The PSU vesting delivered 5,914 common shares, and 3,267 shares were automatically withheld to satisfy tax obligations, leaving her with 123,648 shares of common stock directly owned after these transactions. She also holds multiple non-qualified stock options with various vesting schedules, including some that are fully vested and exercisable.

Vita Coco Company, Inc. Chief Financial Officer Corey Baker reported an equity award in the form of restricted stock units. On February 20, 2026, he acquired 4,401 shares of Common Stock at a stated price of $0.00 per share as a grant or award, bringing his directly held common shares to 43,155.

The restricted stock units will vest in four equal annual installments on each anniversary of the grant date, as long as he remains in continuous service, and shares will be automatically withheld on each vesting date to cover tax obligations. The filing also updates holdings and vesting schedules for several non-qualified stock options that vest in staged annual installments through future dates.

Vita Coco Company, Inc. Executive Chairman Michael Kirban reported equity awards rather than open‑market trades. He acquired performance stock options covering 185,133 shares at 16.91 per share after specified performance conditions were met, and received 25,945 common shares via restricted stock units that vest in four equal annual installments if he remains in continuous service.

Vita Coco Company, Inc. director and Chief Executive Officer Martin Roper reported equity awards and updated holdings. He acquired 185,133 performance options at $16.91 per share and 25,945 shares of common stock through restricted stock units granted at $0.00 per share.

The filing notes that the restricted stock units vest in four equal annual installments, with shares automatically withheld at each vesting date to cover tax obligations. A performance-based stock option vested as to 185,133 shares on February 20, 2026 after its performance conditions were satisfied. The report also lists various non-qualified stock option holdings and indirect common stock holdings through family trusts and the reporting person’s spouse.

Vita Coco Company, Inc. director Jane Cecil Morreau reported option exercises and a related share sale. On February 23, 2026, she exercised non-qualified stock options in three steps, converting them into a total of 15,000 shares of common stock at $10.178 per share.

That same day she sold 15,000 shares of Vita Coco common stock at an average price of $53.91 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. After these transactions, she directly owned 17,179 common shares of Vita Coco.

Vita Coco Company, Inc. director Kenneth Sadowsky reported an open-market sale of common stock. He sold 3,900 shares of common stock at a weighted average price of $55.64 per share in transactions executed under a pre-arranged Rule 10b5-1 trading plan.

After this sale, Sadowsky holds 604,366 shares of Vita Coco common stock directly. He also holds a non-qualified stock option for 27,300 shares that is fully vested and currently exercisable, providing additional potential equity exposure beyond his current common share holdings.

Vita Coco Company, Inc. director Ira Liran reported planned stock sales under a Rule 10b5-1 trading plan. On February 5, 2026, he sold 20,000 shares of common stock directly at a weighted average price of $56.66, leaving 478,341 shares held directly.

On the same date, an additional 30,000 shares of common stock were sold indirectly at a weighted average price of $56.65, with 572,579 shares held indirectly by the Ira Liran 2012 Family Trust. Both reported prices reflect multiple trades within stated intraday price ranges.

Vita Coco Company, Inc. director Kenneth Sadowsky reported selling 3,900 shares of common stock on January 21, 2026 at a weighted average price of $53.92 per share. The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan, meaning the trades were scheduled in advance.

After this transaction, Sadowsky beneficially owned 608,266 shares of Vita Coco common stock in direct ownership. He also holds a non-qualified stock option to buy 27,300 shares of common stock at an exercise price of $10.178 per share, which is fully vested and currently exercisable and expires on January 2, 2030.

Vita Coco Company, Inc. director Shelley G. Broader reported an equity award of 520 shares of common stock in the form of restricted stock units (RSUs) on 01/07/2026. The RSUs were granted at a price of $0.00 per share under the company’s 2021 Incentive Award Plan.

The 520 RSUs vest in full on the earlier of the day immediately preceding the next annual stockholders meeting after the grant date or the first anniversary of the grant date, as long as Broader remains in continuous service through the applicable vesting date. Following this grant, Broader beneficially owns 520 common shares directly.

Vita Coco Company, Inc. Chief Operating Officer Jonathan Burth reported a charitable stock donation and his current equity holdings. On December 18, 2025, he donated 666 shares of Vita Coco common stock to a donor-advised fund for charitable purposes, leaving him with 73,847 common shares held directly.

He also reported multiple non-qualified stock options to buy Vita Coco common stock at exercise prices ranging from $10.178 to $33.36, with expiration dates between December 16, 2029 and March 4, 2035. Several of these options are fully vested and currently exercisable, while others vest in equal annual installments beginning on dates from November 27, 2022 through future grant anniversaries, contingent on continued service.

Vita Coco Company, Inc. director Kenneth Sadowsky reported selling 3,900 shares of common stock on 12/17/2025 at a weighted average price of $51.621 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to trade according to a preset schedule.

After this transaction, Sadowsky beneficially owns 612,166 shares of Vita Coco common stock directly. He also holds a fully vested, currently exercisable non-qualified stock option to buy 27,300 shares of common stock at an exercise price of $10.178 per share, expiring on 01/02/2030.

Vita Coco Company, Inc. (COCO) Chief Executive Officer and director Martin Roper reported an indirect charitable transfer of company stock. On 11/25/2025, his spouse donated 20,000 shares of Vita Coco common stock to a donor-advised fund for charitable purposes, recorded as a disposition at a price of $0.0 per share. Following this transaction, Roper reports 41,200 shares held indirectly by his spouse and 281,562 shares held directly, along with additional indirect holdings through three exempt family trusts. He also holds several non-qualified stock options to purchase Vita Coco common stock, including options for 579,670 shares at an exercise price of $10.178 per share that are fully vested and currently exercisable, plus other option grants with exercise prices ranging from $15 to $32.78 and expirations between 2029 and 2035.

Vita Coco Company, Inc. director trade disclosure: A reporting person related to Vita Coco (ticker COCO) sold shares of common stock on 11/24/2025 under a pre-arranged Rule 10b5-1 trading plan. The transactions included sales of 25,381 shares at a weighted average price of $50.294 and 33,862 shares at a weighted average price of $50.271.

Following these sales, the reporting person held 498,341 shares of Vita Coco common stock directly and 602,579 shares indirectly through the Ira Liran 2012 Family Trust. The prices reflect multiple trades within stated ranges, and detailed trade-by-trade pricing is available upon request as noted in the disclosure.

Vita Coco Company, Inc. (COCO) director Kenneth Sadowsky reported selling 3,900 shares of common stock on 11/19/2025 in an open-market transaction coded as “S.” The weighted average sale price was $47.115 per share, with individual trades executed between $46.32 and $47.45. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Sadowsky beneficially owns 616,066 Vita Coco common shares directly. He also holds a non-qualified stock option to purchase 27,300 shares at an exercise price of $10.178 per share, which is fully vested and exercisable and expires on 01/02/2030.

The Vita Coco Company, Inc. (COCO) chief sales officer Charles Van Es reported an option exercise and share sale. On 11/17/2025 he exercised 20,000 non-qualified stock options for common stock at an exercise price of $10.178 per share and acquired 20,000 shares. On the same day, he sold 20,000 shares of common stock at $50 per share under a Rule 10b5-1 trading plan. After these transactions, he beneficially owned 84,328 shares of common stock directly, along with multiple option grants that are vested or vest over time through 2035.

Vita Coco Company, Inc. (COCO) director Ira Liran reported open-market sales of company stock under a pre-arranged Rule 10b5-1 trading plan. On 11/17/2025, he sold 14,619 shares of common stock at a weighted average price of $50.102 per share and another 26,138 shares at a weighted average price of $50.086 per share, with the latter held indirectly.

After these transactions, Liran beneficially owned 523,722 shares of Vita Coco common stock directly and 636,441 shares indirectly through the Ira Liran 2012 Family Trust. The filing notes that the sales prices reflect weighted averages across multiple trades between $50.00 and $50.47 per share.

Vita Coco Company, Inc. (COCO) Chief Operating Officer Jonathan Burth reported option exercises and share sales of company stock. On 11/17/2025, he exercised 17,666 stock options at an exercise price of $10.178 per share and sold 17,666 common shares in a separate transaction at a weighted average price of $48.684 per share under a Rule 10b5-1 trading plan. The same day, he exercised an additional 20,000 options at $10.178 per share and sold 20,000 shares at a weighted average price of $50.019 per share. Following these transactions, he directly held 76,127 shares of common stock and a significant number of vested and unvested non-qualified stock options with various exercise prices and expiration dates.

Vita Coco Company, Inc. (COCO) reported an insider transaction by Executive Chairman and Director Michael Kirban. On 11/14/2025, a Rule 10b5-1 trading plan sale of 5,102 shares of common stock was executed at $44 per share. After this trade, Kirban beneficially owns 127,629 shares directly, 1,479,049 shares indirectly through the Michael Kirban 2010 Trust, and 615,681 shares indirectly through the Michael Kirban Revocable Trust.

Kirban also holds several non-qualified stock options, including 546,000 options with a $10.178 exercise price expiring 12/16/2029 and other grants with exercise prices ranging from $15 to $32.78 and expirations through 03/03/2035. Some options are fully vested and currently exercisable, while others vest in four equal annual installments starting on specified dates.

Vita Coco Company, Inc. (COCO) reported an insider transaction by a director. On 11/14/2025, the reporting person exercised a non-qualified stock option to acquire 10,000 shares of common stock at an exercise price of $10.178 per share and then sold 10,000 shares at a weighted average price of $43.7226 per share under a Rule 10b5-1 trading plan. Following these transactions, the reporting person beneficially owned 12,162 shares of common stock directly and held 20,675 stock options, which are fully vested and currently exercisable, with an expiration date of 12/16/2029.

Vita Coco Company, Inc. (COCO) director Ira Liran reported open‑market sales of company stock executed under a Rule 10b5‑1 trading plan. On 11/05/2025, he sold a total of 50,000 shares in two tranches: 20,000 shares at a weighted‑average price of $41.404 and 30,000 shares at a weighted‑average price of $41.407. The sales were completed across multiple transactions within the disclosed price range.

Following these transactions, Liran beneficially owns 538,341 shares directly and 662,579 shares indirectly through the Ira Liran 2012 Family Trust.

Vita Coco (COCO) reported an insider transaction by its Chief Marketing Officer, Jane Prior. On 10/29/2025, she exercised 10,000 stock options at $10.178 per share and, on the same day, sold 10,000 shares at an average price of $45.242. The sales were made pursuant to a Rule 10b5-1 trading plan.

Following these transactions, she beneficially owns 123,666 shares directly. The filing also lists multiple outstanding non‑qualified stock option grants with various exercise prices and expiration dates.

Vita Coco Company, Inc. (COCO) director Ira Liran reported the sale of 40,000 shares of common stock on 10/29/2025 under a Rule 10b5-1 trading plan. The weighted average sale price was $45.577, with individual transactions ranging from $44.07 to $48.00.

Following the transactions, Liran held 558,341 shares directly and 692,579 shares indirectly through the Ira Liran 2012 Family Trust.

Vita Coco (COCO) Executive Chairman and Director Michael Kirban reported open‑market sales made under a Rule 10b5‑1 trading plan. He sold 30,000 shares at $45.701 on 10/29/2025 and 14,898 shares at a weighted average price of $44.211 on 10/30/2025.

The 10/30 transactions occurred in multiple trades between $44.00 and $45.00. Following the reported sales, beneficial ownership reported included 1,484,151 shares held indirectly by the Michael Kirban 2010 Trust, plus 127,629 shares held directly and 615,681 shares held indirectly by the Michael Kirban Revocable Trust.

Reported derivative holdings include non‑qualified stock options to purchase 546,000 shares at $10.178 expiring 12/16/2029 (fully vested), 298,507 shares at $15 expiring 10/21/2031, and 70,715 shares at $32.78 expiring 03/03/2035, among others, with specified vesting schedules.

Vita Coco (COCO) reported insider activity by Chief Operating Officer Jonathan Burth. On 10/29/2025, he exercised stock options at $10.178 per share for 2,334 and 20,000 shares (code M), then sold the same amounts (code S) at weighted average prices of $47.948 and $45.711, respectively, pursuant to a Rule 10b5-1 trading plan.

Following these transactions, Burth directly beneficially owned 76,127 shares of common stock. The filing also lists multiple outstanding non-qualified stock options with stated exercise prices and expirations, including grants expiring between 2029 and 2035, with various vesting schedules as disclosed.

Vita Coco (COCO) CEO and Director Martin Roper filed a Form 4 reporting open-market sales of common stock on 10/29/2025 and 10/30/2025 made under a Rule 10b5-1 trading plan.

Direct transactions included 5,000 shares at a weighted average price of $46.087 on 10/29 and 500 shares at $45.00 on 10/30. Indirect transactions included 5,000 shares at a weighted average $46.108 on 10/29 and 500 shares at $45.00 on 10/30 by the Christopher G. Roper Exempt Family Trust, plus 5,000 shares each on 10/29 by the Peter S. Roper and Thomas L. Roper Exempt Family Trusts at weighted average prices within the disclosed ranges.

Following these transactions, reported beneficial holdings were 281,562 shares (direct), 215,631 (Christopher G. Roper Exempt Family Trust), 216,131 (Peter S. Roper Exempt Family Trust), 216,131 (Thomas L. Roper Exempt Family Trust), and 61,200 (by spouse).

Vita Coco Company (COCO) reported an insider transaction by a director. On 10/15/2025, the reporting person sold 3,900 shares of common stock at a weighted average price of $38.915 under a Rule 10b5-1 trading plan. Following the sale, the insider directly beneficially owns 619,966 shares.

The filing also lists a non-qualified stock option to buy 27,300 shares at an exercise price of $10.178, fully vested and currently exercisable, with an expiration date of 01/02/2030.

Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported sales of a total of 7,894 shares of common stock on 10/07/2025 under a Rule 10b5-1 trading plan at weighted average prices in the range of approximately $42.51–$42.91. After the transactions the filing reports 287,062 shares beneficially owned directly and 221,131 shares held indirectly through family trusts. The filing also discloses outstanding non-qualified stock options exercisable for 1,099,460 shares in aggregate, with several option grants fully vested and others vesting in scheduled installments through 2035. The sales were effected pursuant to a pre-established plan and the form was signed by an attorney-in-fact on behalf of the reporting person.

Vita Coco Company, Inc. (COCO) reported insider sales by Martin Roper executed under a Rule 10b5-1 trading plan. The filing shows multiple dispositions of 5,000 shares on 10/03/2025 and 10/06/2025, with reported weighted-average prices around $42.6–$42.9. After the reported sales, Mr. Roper directly beneficially owned 293,897 shares and held indirect interests through family trusts and related parties; several family trusts show remaining indirect holdings in the low- to mid-200,000s.

The form also lists fully vested and exercisable non-qualified stock options and other option grants: a large exercisable option for 579,670 shares at an exercise price of $10.178, plus additional option tranches totaling several hundred thousand shares with exercise prices from $10.178 to $32.78 and various vesting/expiration dates through 2035. The sales were made pursuant to a 10b5-1 plan; the filer offered to provide transaction-level price details on request.

Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported multiple sales of company common stock under a Rule 10b5-1 trading plan executed on 10/01/2025 and 10/02/2025. The filings show repeated disposals of 5,000-share blocks at weighted average prices in the low $42 range (reported ranges between $41.79 and $42.66). Following the reported 10/01 sale the filing shows 303,897 shares beneficially owned directly; following the 10/02 sale that direct ownership is shown as 298,897. The Form 4 also discloses multiple indirect holdings by related family trusts and a spouse, and reports several non-qualified stock options with exercise prices from $10.178 to $32.78, some fully vested and currently exercisable and others subject to multi-year vesting schedules.

Insider transactions by Vita Coco Company, Inc. (COCO) show the chief operating officer engaged in a planned sale of 3,173 shares of common stock under a Rule 10b5-1 trading plan at $42.50 per share, which reduced his direct holdings from 79,300 to 76,127 shares. The filing also reports the grant and continued ownership of multiple non-qualified stock options with exercise prices ranging from $10.178 to $33.36, some fully vested and exercisable and others subject to multi-year vesting schedules. The disclosure records routine option grants and an executed plan-based sale, providing transparency about executive equity and compensation.

Insider sales by Vita Coco CEO and related trusts. Martin Roper reported multiple Rule 10b5-1 sales of common stock on September 24-25, 2025, disposing of blocks of 5,000 and 400 shares at weighted average prices in the ~$40.00–$41.67 range. After these transactions the reporting person directly held 319,297 shares. Related family trusts and spouses show indirect holdings ranging from 252,515 to 253,931 shares, and an additional 61,200 shares are held by a spouse. The filing also discloses large outstanding stock option positions fully exercisable or vesting across 2022–2026, totaling several hundred thousand underlying shares.

Martin Roper, CEO and Director of Vita Coco Company, Inc. (COCO), reported open-market sales of common stock executed under a Rule 10b5-1 trading plan on September 22 and 23, 2025. The filing shows two sales by the reporting person of 5,000 shares on 09/22/2025 and 5,000 shares on 09/23/2025 at weighted-average prices in the ~$40.14–$40.52 range, leaving 324,297 shares held directly after the 09/23 sale. The form also discloses multiple indirect holdings through family trusts and a spouse, and a total of 1,099,460 outstanding stock options across several grant dates and exercise prices, including fully vested options exercisable now.

Michael Kirban, Executive Chairman and Director of Vita Coco Company, Inc. (COCO), reported transactions on 09/22/2025. He sold 20,000 shares of common stock pursuant to a Rule 10b5-1 trading plan at a weighted average price of $41.535 per share. The Form 4 shows he beneficially owns 1,529,049 shares indirectly through the Michael Kirban 2010 Trust and additional holdings reflected as direct and indirect positions. The filing also lists multiple outstanding non-qualified stock options with exercise prices from $10.178 to $32.78 and varying vesting or exercisability dates.

Martin Roper, a director and CEO of Vita Coco Company, Inc. (COCO), amended a Form 4 to report multiple sales of common stock executed pursuant to a Rule 10b5-1 trading plan on September 15–17, 2025. The Form 4/A shows a series of disposals reported as sales (code S) that reduced both direct and indirect beneficial holdings and reports weighted-average prices for the transactions in ranges approximately between $40.00 and $40.54 per share. The filing also discloses several fully vested and unvested non‑qualified stock options exercisable for large blocks of common stock, with exercise prices from $10.178 to $32.78 and various vesting schedules and expiration dates through 2035. The amendment restates the original Form 4 filed September 18, 2025.

Vita Coco insider Form 4: Martin Roper stock sales and option holdings. The filing reports that Martin Roper, CEO and director, sold four blocks of common stock on 09/18/2025 pursuant to a Rule 10b5-1 trading plan, disposing of 5,000 shares in his name and 5,000 shares each tied to three family trusts for a total reported disposals of 20,000 shares at weighted average prices around $40.00–$40.11 per share. The filing also discloses substantial currently exercisable and non-exercisable non-qualified stock options totaling 1,098,460 underlying shares across multiple grants with exercise prices ranging from $10.178 to $32.78.